| 
	   In the lung, airway epithelia function  as the first defense line against the invasion of air-borne pathogens. The two  major cell types in airway epithelia are goblet cells and multiciliated cells  (MCCs). Sticky mucus secreted by goblet cells to the surface of airway  epithelia trap inhaled pathogens like virus, bacteria, and other  micro-organisms; and the coordinated beating of cilia on top of MCCs sweep away  the dirty mucus to keep airway clean. In motile cilia-related lung disorders  like Primary Ciliary Dyskinesia (PCD) and Chronic Obstructive Pulmonary Disease  (COPD), airway motile cilia are defective. And without the service of airway  motile cilia, mucus will accumulate in the airway and eventually block the  airway, pathogens inside mucus can irritate the airway and trigger infection.  The causes of ciliary defects in these two respiratory diseases are distinct:  in PCD, genetic faults lead to underdeveloped motile cilia, which is inherited;  in COPD, tobacco smoking results in shortening and various damages of airway  motile cilia, which is acquired. Our past study has shown that a microRNA gene  family, mir-34/449, is required for the development of motile cilia. Removal of  this gene family in mice leads to a significant decrease in both length and  number of airway motile cilia, and consequently the mir-34/449 deficient mice  develop the PCD symptoms. Consistent with the crucial roles of miR-34/449 miRNAs  in airway MCCs, a remarkable decrease of miR-34/449 expression in the lung has  been shown to be a response to tobacco smoking and associated with COPD  progression. Therefore, a deeper understanding of miR-34/449 miRNAs in airway MCCs  will provide essential preliminary data to support the development of an early  detection and a treatment of motile cilia-related lung disorders like PCD and  COPD. This proposal aims to generate a comprehensive and detailed picture of  miR-34/449 miRNAs in mouse and human airway MCCs, and test the feasibility of  using miR-34/449 miRNAs and downstream targets to treat motile-cilia related  lung diseases. This work will have significant implications on both basic  biology and potential clinical applications. 	   |